Timothy Caulfield

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/225367/publications.pdf

Version: 2024-02-01

200 papers

6,197 citations

70961 41 h-index 95083 68 g-index

207 all docs

207 docs citations

207 times ranked

5744 citing authors

#	Article	IF	CITATIONS
1	Science communication reconsidered. Nature Biotechnology, 2009, 27, 514-518.	9.4	327
2	Stem Cell Clinics Online: The Direct-to-Consumer Portrayal of Stem Cell Medicine. Cell Stem Cell, 2008, 3, 591-594.	5.2	305
3	Research Ethics Recommendations for Whole-Genome Research: Consensus Statement. PLoS Biology, 2008, 6, e73.	2.6	212
4	Research ethics and the challenge of whole-genome sequencing. Nature Reviews Genetics, 2008, 9, 152-156.	7.7	201
5	Setting Global Standards for Stem Cell Research and Clinical Translation: TheÂ2016 ISSCR Guidelines. Stem Cell Reports, 2016, 6, 787-797.	2.3	172
6	Deflating the Genomic Bubble. Science, 2011, 331, 861-862.	6.0	161
7	Ethics and Genomic Incidental Findings. Science, 2013, 340, 1047-1048.	6.0	160
8	Marketing of unproven stem cell–based interventions: A call to action. Science Translational Medicine, 2017, 9, .	5.8	147
9	DNA databanks and consent: A suggested policy option involving an authorization model. BMC Medical Ethics, 2003, 4, E1.	1.0	112
10	Direct-to-Consumer Genetic Testing: Perceptions, Problems, and Policy Responses. Annual Review of Medicine, 2012, 63, 23-33.	5.0	109
11	Confronting stem cell hype. Science, 2016, 352, 776-777.	6.0	109
12	Race and ancestry in biomedical research: exploring the challenges. Genome Medicine, 2009, $1,8$.	3.6	106
13	Evidence and anecdotes: an analysis of human gene patenting controversies. Nature Biotechnology, 2006, 24, 1091-1094.	9.4	101
14	Broad Consent in Biobanking: Reflections on Seemingly Insurmountable Dilemmas. Medical Law International, 2009, 10, 85-100.	0.4	95
15	Biobanks, consent and claims of consensus. Nature Methods, 2012, 9, 885-888.	9.0	87
16	A review of the key issues associated with the commercialization of biobanks. Journal of Law and the Biosciences, 2014, 1, 94-110.	0.8	87
17	Personal medicine—the new banking crisis. Nature Biotechnology, 2012, 30, 141-147.	9.4	83
18	Genes, cells, and biobanks: Yes, there's still a consent problem. PLoS Biology, 2017, 15, e2002654.	2.6	82

#	Article	IF	Citations
19	Biobanks and Blanket Consent: The Proper Place of the Public Good and Public Perception Rationales. King's Law Journal, 2007, 18, 209-226.	0.3	77
20	Biotechnology and the popular press: hype and the selling of science. Trends in Biotechnology, 2004, 22, 337-339.	4.9	75
21	Reassessing direct-to-consumer portrayals of unproven stem cell therapies: is it getting better?. Regenerative Medicine, 2013, 8, 361-369.	0.8	73
22	Stem cell hype: Media portrayal of therapy translation. Science Translational Medicine, 2015, 7, 278ps4.	5.8	69
23	iPS Cells: Mapping the Policy Issues. Cell, 2009, 139, 1032-1037.	13.5	68
24	Reflections on the Cost of "Low-Cost" Whole Genome Sequencing: Framing the Health Policy Debate. PLoS Biology, 2013, 11, e1001699.	2.6	67
25	Pseudoscience and COVID-19 — we've had enough already. Nature, 2020, , .	13.7	61
26	Stem cell clinics in the news. Nature Biotechnology, 2010, 28, 1243-1246.	9.4	59
27	Angelina Jolie's faulty gene: newspaper coverage of a celebrity's preventive bilateral mastectomy in Canada, the United States, and the United Kingdom. Genetics in Medicine, 2014, 16, 522-528.	1.1	58
28	Stem Cell Tourism and Doctors' Duties to Minorsâ€"A View From Canada. American Journal of Bioethics, 2010, 10, 3-15.	0.5	56
29	Representing a "revolution†how the popular press has portrayed personalized medicine. Genetics in Medicine, 2018, 20, 950-956.	1.1	54
30	The Future of Personal Genomics. Science, 2007, 317, 1687-1687.	6.0	53
31	Human dignity: a guide to policy making in the biotechnology era?. Nature Reviews Genetics, 2006, 7, 72-76.	7.7	50
32	Myriad and the mass media: the covering of a gene patent controversy. Genetics in Medicine, 2007, 9, 850-855.	1.1	50
33	Emerging Ethical, Legal and Social Issues Associated with Stem Cell Research & Empry and the Current Role of the Moral Status of the Embryo. Stem Cell Reviews and Reports, 2009, 5, 96-101.	5.6	49
34	Biobanking, Consent, and Control: A Survey of Albertans on Key Research Ethics Issues. Biopreservation and Biobanking, 2012, 10, 433-438.	0.5	49
35	The commercialization of university-based research: Balancing risks and benefits. BMC Medical Ethics, 2015, 16, 70.	1.0	48
36	Celebrities' impact on health-related knowledge, attitudes, behaviors, and status outcomes: protocol for a systematic review, meta-analysis, and meta-regression analysis. Systematic Reviews, 2017, 6, 13.	2.5	48

#	Article	IF	CITATIONS
37	Role and reality: technology transfer at Canadian universities. Trends in Biotechnology, 2010, 28, 447-451.	4.9	47
38	Open science versus commercialization: a modern research conflict?. Genome Medicine, 2012, 4, 17.	3.6	46
39	Implicit hype? Representations of platelet rich plasma in the news media. PLoS ONE, 2017, 12, e0182496.	1.1	46
40	Restricting marketing to children: Consensus on policy interventions to address obesity. Journal of Public Health Policy, 2013, 34, 239-253.	1.0	44
41	Exploiting science? A systematic analysis of complementary and alternative medicine clinic websites' marketing of stem cell therapies. BMJ Open, 2018, 8, e019414.	0.8	44
42	Regulating Direct-to-Consumer Personal Genome Testing. Science, 2010, 330, 181-182.	6.0	43
43	Scientists' perspectives on consent in the context of biobanking research. European Journal of Human Genetics, 2015, 23, 569-574.	1.4	43
44	Stem Cell Tourism and Public Education: The Missing Elements. Cell Stem Cell, 2014, 15, 267-270.	5.2	42
45	New ISSCR guidelines: clinical translation of stem cell research. Lancet, The, 2016, 387, 1979-1981.	6.3	42
46	Health Misinformation and the Power of Narrative Messaging in the Public Sphere. Canadian Journal of Bioethics, 0, 2, 52-60.	0.0	42
47	Policy: Global standards for stem-cell research. Nature, 2016, 533, 311-313.	13.7	41
48	The Stem Cell Research Environment: A Patchwork of Patchworks. Stem Cell Reviews and Reports, 2009, 5, 82-88.	5.6	40
49	Patenting human genetic material: refocusing the debate. Nature Reviews Genetics, 2000, 1, 227-231.	7.7	39
50	Harm, hype and evidence: ELSI research and policy guidance. Genome Medicine, 2013, 5, 21.	3.6	39
51	A critical analysis of obesity prevention policies and strategies. Canadian Journal of Public Health, 2017, 108, e598-e608.	1.1	39
52	Trust, patents and public perceptions: the governance of controversial biotechnology research. Nature Biotechnology, 2006, 24, 1352-1354.	9.4	38
53	Fake news portrayals of stem cells and stem cell research. Regenerative Medicine, 2017, 12, 765-775.	0.8	38
54	Addressing Internalized Weight Bias and Changing Damaged Social Identities for People Living With Obesity. Frontiers in Psychology, 2019, 10, 1409.	1.1	38

#	Article	IF	CITATIONS
55	The Commercialisation of Medical and Scientific Reporting. PLoS Medicine, 2004, 1, e38.	3.9	37
56	Spinning the Genome: Why Science Hype Matters. Perspectives in Biology and Medicine, 2018, 61, 560-571.	0.3	36
57	How to Peddle Hope: An Analysis of YouTube Patient Testimonials ofÂUnproven Stem Cell Treatments. Stem Cell Reports, 2019, 12, 1186-1189.	2.3	35
58	From genomic medicine to precision medicine: highlights of 2015. Genome Medicine, 2016, 8, 12.	3.6	32
59	COVID-19 and â€~immune boosting' on the internet: a content analysis of Google search results. BMJ Open, 2020, 10, e040989.	0.8	31
60	Informed consent in embryonic stem cell research: Are we following basic principles?. Cmaj, 2007, 176, 1722-1725.	0.9	30
61	"lmmune Boosting―in the time of COVID: selling immunity on Instagram. Allergy, Asthma and Clinical Immunology, 2020, 16, 76.	0.9	30
62	Crowdfunding Cannabidiol (CBD) for Cancer: Hype and Misinformation on GoFundMe. American Journal of Public Health, 2020, 110, S294-S299.	1.5	30
63	Societal Values in the Allocation of Healthcare Resources. Patient, 2011, 4, 207-225.	1.1	29
64	Athletes' Use of Unproven Stem Cell Therapies: Adding to Inappropriate Media Hype?. Molecular Therapy, 2012, 20, 1656-1658.	3.7	29
65	Policy Statement of Canadian Society of Transplantation and Canadian Society of Nephrology on Organ Trafficking and Transplant Tourism. Transplantation, 2010, 90, 817-820.	0.5	28
66	Professional Regulation: A Potentially Valuable Tool in Responding to "StemÂCell Tourism― Stem Cell Reports, 2014, 3, 379-384.	2.3	28
67	Stem cell tourism and Canadian family physicians. Canadian Family Physician, 2012, 58, 365-8, e182-5.	0.1	28
68	A systematic review of how homeopathy is represented in conventional and CAM peer reviewed journals. BMC Complementary and Alternative Medicine, 2005, 5, 12.	3.7	27
69	What's Missing? Discussing Stem Cell Translational Research in Educational Information on Stem Cell "Tourism― Journal of Law, Medicine and Ethics, 2013, 41, 254-268.	0.4	26
70	Stem Cell Research and Economic Promises. Journal of Law, Medicine and Ethics, 2010, 38, 303-313.	0.4	25
71	Direct-to-consumer testing: if consumers are not anxious, why are policymakers?. Human Genetics, 2011, 130, 23-25.	1.8	25
72	The Evolution of Policy Issues in Stem Cell Research: An International Survey. Stem Cell Reviews and Reports, 2012, 8, 1037-1042.	5.6	25

#	Article	IF	CITATIONS
73	Representations of the health value of vitamin D supplementation in newspapers: media content analysis. BMJ Open, 2014, 4, e006395.	0.8	25
74	Representations of Stem Cell Clinics on Twitter. Stem Cell Reviews and Reports, 2014, 10, 753-760.	5.6	25
75	Let's do better: public representations of COVID-19 science. Facets, 2021, 6, 403-423.	1.1	25
76	Patents, commercialization and the Canadian stem cell research community. Regenerative Medicine, 2008, 3, 483-496.	0.8	24
77	Newspaper reporting on legislative and policy interventions to address obesity: United States, Canada, and the United Kingdom. Journal of Public Health Policy, 2011, 32, 73-90.	1.0	24
78	Human Dignity as a Criterion for Science Policy. PLoS Medicine, 2005, 2, e244.	3.9	23
79	Stem cell research policy and iPS cells. Nature Methods, 2010, 7, 28-33.	9.0	23
80	Evaluating the "family veto―of consent for organ donation. Cmaj, 2016, 188, E436-E437.	0.9	23
81	Direct-To-Consumer Genetics and Health Policy: A Worst-Case Scenario?. American Journal of Bioethics, 2009, 9, 48-50.	0.5	22
82	Selling falsehoods? A cross-sectional study of Canadian naturopathy, homeopathy, chiropractic and acupuncture clinic website claims relating to allergy and asthma. BMJ Open, 2016, 6, e014028.	0.8	22
83	CRISPR in the North American popular press. Genetics in Medicine, 2019, 21, 2184-2189.	1.1	21
84	Research ethics and stem cells. EMBO Reports, 2015, 16, 2-6.	2.0	20
85	Injecting doubt: responding to the naturopathic anti-vaccination rhetoric. Journal of Law and the Biosciences, 2017, 4, 229-249.	0.8	20
86	Media portrayal of illness-related medical crowdfunding: A content analysis of newspaper articles in the United States and Canada. PLoS ONE, 2019, 14, e0215805.	1.1	20
87	Stem Cell Research Ethics: Consensus Statement on Emerging Issues. Journal of Obstetrics and Gynaecology Canada, 2007, 29, 843-848.	0.3	19
88	The Fountain of Stem Cell-Based Youth? Online Portrayals of Anti-Aging Stem Cell Technologies. Aesthetic Surgery Journal, 2015, 35, 730-736.	0.9	19
89	Trafficking in Human Beings for the Purpose of Organ Removal and the Ethical and Legal Obligations of Healthcare Providers. Transplantation Direct, 2016, 2, e60.	0.8	19
90	Ethics Hype?. Hastings Center Report, 2016, 46, 13-16.	0.7	19

#	Article	IF	CITATIONS
91	Non-invasive Prenatal Testing and the Unveiling of an Impaired Translation Process. Journal of Obstetrics and Gynaecology Canada, 2017, 39, 10-17.	0.3	19
92	Canadian Newspaper Coverage of the A/H1N1 Vaccine Program. Canadian Journal of Public Health, 2011, 102, 200-203.	1.1	18
93	Financial Incentives to Increase Canadian Organ Donation: Quick Fix or Fallacy?. American Journal of Kidney Diseases, 2014, 63, 133-140.	2.1	18
94	The media and access issues: content analysis of Canadian newspaper coverage of health policy decisions. Orphanet Journal of Rare Diseases, 2015, 10, 102.	1.2	18
95	The role of digital tools in the delivery of genomic medicine: enhancing patient-centered care. Genetics in Medicine, 2021, 23, 1086-1094.	1.1	18
96	COVID-19 and Vitamin D Misinformation on YouTube: Content Analysis. JMIR Infodemiology, 2022, 2, e32452.	1.0	17
97	Gordie Howeâ∈™s Stem Cell â€~Miracleâ∈™: A Qualitative Analysis of News Coverage and Readers' Comment Newspapers and Sports Websites. Stem Cell Reviews and Reports, 2015, 11, 667-675.	ts in 5.6	16
98	"Neurohype―and the Name Game: Who's to Blame?. AJOB Neuroscience, 2010, 1, 13-15.	0.6	15
99	Gordie Howe's "Miraculous Treatment†Case Study of Twitter Users' Reactions to a Sport Celebrityâ Stem Cell Treatment. JMIR Public Health and Surveillance, 2016, 2, e8.	€™s 1.2	15
100	Eugenic Policies in Alberta: From the Systematic to the Systemic. Alberta Law Review, 1996, 35, 59.	0.2	15
101	Supported by science?: What Canadian naturopaths advertise to the public. Allergy, Asthma and Clinical Immunology, 2011, 7, 14.	0.9	14
102	Non-refundable Tax Credits Are an Inequitable Policy Instrument for Promoting Physical Activity Among Canadian Children. Canadian Journal of Public Health, 2012, 103, 175-177.	1.1	14
103	Human gene editing: revisiting Canadian policy. Npj Regenerative Medicine, 2017, 2, 3.	2.5	14
104	Patients' crowdfunding campaigns for alternative cancer treatments. Lancet Oncology, The, 2019, 20, 28-29.	5.1	14
105	Human cloning laws, human dignity and the poverty of the policy making dialogue. BMC Medical Ethics, 2003, 4, E3.	1.0	13
106	Physician Liability and Non-Invasive Prenatal Testing. Journal of Obstetrics and Gynaecology Canada, 2014, 36, 907-914.	0.3	13
107	The stem cell market and policy options: a call for clarity. Journal of Law and the Biosciences, 2018, 5, 743-758.	0.8	13
108	Crowdfunding for complementary and alternative medicine: What are cancer patients seeking?. PLoS ONE, 2020, 15, e0242048.	1.1	13

#	Article	IF	CITATIONS
109	Media portrayal of non-invasive prenatal testing: a missing ethical dimension. Journal of Science Communication, 2016, 15, A03.	0.4	13
110	Policy Conflicts: Gene Patents and Health Care in Canada. Public Health Genomics, 2005, 8, 223-227.	0.6	12
111	Chinese Newspaper Coverage of (Unproven) Stem Cell Therapies and their Providers. Stem Cell Reviews and Reports, 2013, 9, 111-118.	5.6	12
112	Policy recommendations for addressing privacy challenges associated with cell-based research and interventions. BMC Medical Ethics, 2014, 15, 7.	1.0	12
113	Marginally scientific? Genetic testing of children and adolescents for lifestyle and health promotion. Journal of Law and the Biosciences, 2015, 2, lsv038.	0.8	12
114	Controversies with Kalydeco: Newspaper coverage in Canada and the United States of the cystic fibrosis "wonder drug― Journal of Cystic Fibrosis, 2016, 15, 624-629.	0.3	12
115	Industry involvement in publicly funded biobanks. Nature Reviews Genetics, 2014, 15, 220-220.	7.7	11
116	Defining â€~medical necessity' in an age of personalised medicine: A view from Canada. BioEssays, 2014, 36, 813-817.	1,2	11
117	SafetyNET: An interdisciplinary research program to support a safety culture for spinal manipulation therapy. European Journal of Integrative Medicine, 2014, 6, 473-477.	0.8	11
118	Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action. BMC Medical Ethics, 2019, 20, 51.	1.0	11
119	Legal and ethical issues associated with patient recruitment in clinical trials: the case of competitive enrolment. Health Law Review, 2005, 13, 58-61.	0.1	11
120	Biomedical Research and the Commercialization Agenda: A Review of main Considerations for Neuroscience. Accountability in Research, 2008, 15, 303-320.	1.6	10
121	The Challenge of Regulating Rapidly Changing Science: Stem Cell Legislation in Canada. Cell Stem Cell, 2009, 4, 285-288.	5.2	10
122	Tracing the use and source of racial terminology in representations of genetic research. Genetics in Medicine, 2011, 13, 314-319.	1.1	9
123	The "subluxation―issue: an analysis of chiropractic clinic websites. Archives of Physiotherapy, 2019, 9, 11.	0.7	9
124	Policy Challenges for Organ Allocation in an Era of "Precision Medicine― Canadian Journal of Kidney Health and Disease, 2020, 7, 205435812091265.	0.6	9
125	The consumer representation of DNA ancestry testing on YouTube. New Genetics and Society, 2021, 40, 133-154.	0.7	9
126	Discussing nonâ€invasive prenatal testing on Reddit: The benefits, the concerns, and the comradery. Prenatal Diagnosis, 2021, 41, 100-110.	1.1	9

#	Article	IF	CITATIONS
127	Crowdfunding Campaigns and COVID-19 Misinformation. American Journal of Public Health, 2021, 111, 739-742.	1.5	9
128	Chiropractic and Spinal Manipulation Therapy on Twitter: Case Study Examining the Presence of Critiques and Debates. JMIR Public Health and Surveillance, 2016, 2, e153.	1.2	9
129	Gene banks and blanket consent. Nature Reviews Genetics, 2002, 3, 577-577.	7.7	8
130	Gene patents, health care policy and licensing schemes. Trends in Biotechnology, 2006, 24, 251-254.	4.9	8
131	Stem Cell Patents and Social Controversy: A Speculative View from Canada. Medical Law International, 2006, 7, 219-232.	0.4	8
132	Stem cell research, scientific freedom and the commodification concern. EMBO Reports, 2012, 13, 12-16.	2.0	8
133	Position Statement on the Provision and Procurement of Human Eggs for Stem Cell Research. Cell Stem Cell, 2013, 12, 285-291.	5.2	8
134	Incentives and Organ Donation: What's (Really) Legal in Canada?. Canadian Journal of Kidney Health and Disease, 2014, 1, 7.	0.6	8
135	The Law and Ethics of Switching from Biologic to Biosimilar in Canada. Journal of the Canadian Association of Gastroenterology, 2020, 3, 228-233.	0.1	8
136	â€~Gut health' and the microbiome in the popular press: a content analysis. BMJ Open, 2021, 11, e052446.	0.8	8
137	Xenotransplantation and Public Health: Identifying the Legal Issues. Canadian Journal of Public Health, 1999, 90, 282-284.	1.1	7
138	Scientific freedom and research cloning: can a ban be justified?. Lancet, The, 2004, 364, 124-126.	6.3	7
139	International stem cell environments: a world of difference. Nature Reports Stem Cells, 2009, , .	0.1	7
140	Nutrigenomics Patents and Commercialization: Old Wine in a New Bottle?. OMICS A Journal of Integrative Biology, 2009, 13, 63-67.	1.0	7
141	Enabling advanced cell therapies (EnACT): invitation to an online forum on resolving barriers to clinical translation. Regenerative Medicine, 2012, 7, 735-740.	0.8	7
142	2012 highlights in translational 'omics. Genome Medicine, 2013, 5, 10.	3.6	7
143	The face of chiropractic: evidenceâ€based?. Focus on Alternative and Complementary Therapies, 2015, 20, 13-22.	0.1	7
144	The gene patent controversy on Twitter: a case study of Twitter users' responses to the CHEO lawsuit against Long QT gene patents. BMC Medical Ethics, 2015, 16, 55.	1.0	7

#	Article	IF	Citations
145	Pragmatic clinical trials and the consent process. Research Ethics, 2018, 14, 1-14.	0.8	7
146	Open science precision medicine in Canada: Points to consider. Facets, 2019, 4, 1-19.	1.1	7
147	Food Allergy Policy and the Popular Press. Journal of Asthma & Allergy Educators, 2011, 2, 282-287.	0.1	6
148	Policy Uncertainty, Sequencing, and Cell Lines. G3: Genes, Genomes, Genetics, 2013, 3, 1205-1207.	0.8	6
149	Family veto in organ donation in Canada: framing within English-language newspaper articles. CMAJ Open, 2017, 5, E768-E772.	1.1	6
150	Geolocalisation of athletes for out-of-competition drug testing: ethical considerations. Position statement by the WADA Ethics Panel. British Journal of Sports Medicine, 2018, 52, 456-459.	3.1	6
151	The law of food allergy and accommodation in Canadian schools. Allergy, Asthma and Clinical Immunology, 2018, 14, 67.	0.9	6
152	A taxonomy of riskâ€associated alternative health practices: A Delphi study. Health and Social Care in the Community, 2022, 30, 1163-1181.	0.7	6
153	Commercialization versus open science: Making sense of the message(s) in the bottle. Medical Law International, 2012, 12, 3-10.	0.4	5
154	Commenting on chiropractic: A YouTube analysis. Cogent Medicine, 2017, 4, 1277450.	0.7	5
155	Portrayal of umbilical cord blood research in the North American popular press: promise or hype?. Regenerative Medicine, 2020, 15, 1228-1237.	0.8	5
156	The law and problematic marketing by private umbilical cord blood banks. BMC Medical Ethics, 2020, 21, 52.	1.0	5
157	Navigating physicians' ethical and legal duties to patients seeking unproven interventions abroad. Canadian Family Physician, 2015, 61, 584-6, e295-8.	0.1	5
158	DNA databanks, public opinion and the law. Clinical and Investigative Medicine, 2002, 25, 252-6.	0.3	5
159	Conflicts of Interest in Clinical Research: Addressing the Issue of Physician Remuneration. Journal of Law, Medicine and Ethics, 2002, 30, 305-308.	0.4	4
160	From Human Embryos to Interspecies Creations: Ethical and Legal Uncertainties Surrounding the Creation of Cytoplasmic Hybrids for Research. Medical Law International, 2008, 9, 227-244.	0.4	4
161	Reflections on the Gene Patent War: The Myriad Battle, Sputnik and Beyond. Clinical Chemistry, 2011, 57, 977-979.	1.5	4
162	Commentary: the law, unproven CAM and the twoâ€hats fallacy. Focus on Alternative and Complementary Therapies, 2012, 17, 4-8.	0.1	4

#	Article	IF	CITATIONS
163	Obesity Genes, Personalized Medicine, and Public Health Policy. Current Obesity Reports, 2015, 4, 319-323.	3.5	4
164	Peddling promise? An analysis of private umbilical cord blood banking company websites in Canada. Cell and Tissue Banking, 2021, 22, 609-622.	0.5	4
165	Newspaper coverage of biobanks. PeerJ, 2014, 2, e500.	0.9	4
166	Research, Digital Health Information and Promises of Privacy: Revisiting the Issue of Consent. Canadian Journal of Bioethics, 0, 3, 164-171.	0.0	4
167	Obesity, legal duties, and the family physician. Canadian Family Physician, 2007, 53, 1129-30, 1133-5.	0.1	4
168	The commercialization of genomic research in Canada. Healthcare Policy, 2010, 6, 24-32.	0.3	4
169	An Investigation of Embryo Donation, Informed Consent, and Research Oversight in Canadian Human Embryonic Stem Cell Research. Journal of Obstetrics and Gynaecology Canada, 2007, 29, 997-1002.	0.3	3
170	Popular Culture Representations of Science: Views from the Canadian Stem Cell Research Community. Stem Cell Reviews and Reports, 2010, 6, 337-339.	5.6	3
171	Legal liability and research ethics boards: The case of neuroimaging and incidental findings. International Journal of Law and Psychiatry, 2012, 35, 137-145.	0.5	3
172	Public Solicitation and The Canadian Media: Two Cases of Living Liver Donation, Two Different Stories. Transplantation Direct, 2019, 5, e508.	0.8	3
173	Newspaper portrayals of spinal manipulation therapy: Canada, United States, and the United Kingdom. Journal of Science Communication, 2013, 12, A02.	0.4	3
174	Physicians' liability and drug formulary restrictions. Cmaj, 2002, 166, 458-60.	0.9	3
175	Analyzing natural herd immunity media discourse in the United Kingdom and the United States. PLOS Global Public Health, 2022, 2, e0000078.	0.5	3
176	Reconsenting paediatric research participants for use of identifying data. Journal of Medical Ethics, 2023, 49, 106-109.	1.0	3
177	Cloning and genetic determinism—a call for consistency. Nature Biotechnology, 2001, 19, 403-403.	9.4	2
178	Legal Foundations for a National Public Health Agency in Canada. Canadian Journal of Public Health, 2005, 96, 281-283.	1.1	2
179	Curbing transplant tourism: Canadian physicians and the law. Cmaj, 2016, 188, 935-936.	0.9	2
180	Influenza vaccination discourse in major Canadian news media, 2017–2018. Heliyon, 2018, 4, e00970.	1.4	2

#	Article	lF	CITATIONS
181	Policy Paradoxes: The Commercialization of Stem Cell Research. , 2012, , .		2
182	Diversifying stem cell debates: Including Muslim contexts and perspectives. Stem Cell Reports, 2022, , .	2.3	2
183	Regulating the genetic revolution. Trends in Molecular Medicine, 1999, 5, 198-200.	2.6	1
184	Directâ€toâ€consumer genetic testing â€" where should we focus the policy debate?. Medical Journal of Australia, 2013, 198, 499-500.	0.8	1
185	The challenge of human challenge research models: A Canadian perspective. Medical Law International, 2017, 17, 273-284.	0.4	1
186	Promotion of Testing for Celiac Disease and the Gluten-Free Diet Among Complementary and Alternative Medicine Practitioners. American Journal of Gastroenterology, 2019, 114, 786-791.	0.2	1
187	Non-Invasive Prenatal Screening: Navigating the Relevant Legal Norms. Journal of Obstetrics and Gynaecology Canada, 2020, 42, 1271-1275.	0.3	1
188	Bill C-13 The Assisted Human Reproduction Act: examining the arguments against a regulatory approach. Health Law Review, 2002, 11, 20-5.	0.1	1
189	Commentary: an independent voice?: conflicts of interest and research on ethical, legal and social issues. Health Law Review, 2005, 13, 114-6.	0.1	1
190	Reply to Ian Dunham. Trends in Molecular Medicine, 1998, 4, 336.	2.6	0
191	Response—Regulating Genetic Tests: Who Owns the Data?. Science, 2010, 330, 1626-1627.	6.0	O
192	Commentary: the law, unproven <scp>CAM</scp> and the referral challenge. Focus on Alternative and Complementary Therapies, 2013, 18, 1-7.	0.1	0
193	Doing Research with Vulnerable Populations: The Case of Intravenous Drug Users. BioéthiqueOnline, 0, 5, .	0.0	0
194	Compelled Disclosure of Confidential Information in Patient Safety Research. Journal of Patient Safety, 2021, 17, 200-206.	0.7	0
195	Discussing <i>The Anatomy Table</i> and <i>The Vaccination Picture</i> . Imaginations: Journal of Cross-Cultural Media Studies, 2020, 11, .	0.0	0
196	Politics, prohibitions and the lost public perspective: a comment on Bill C-56: the Assisted Human Reproduction Act. Alberta Law Review, 2002, 40, 451-63.	0.2	0
197	Crowdfunding for complementary and alternative medicine: What are cancer patients seeking?., 2020, 15, e0242048.		0
198	Crowdfunding for complementary and alternative medicine: What are cancer patients seeking?. , 2020, 15, e0242048.		0

#	Article	IF	CITATIONS
199	Crowdfunding for complementary and alternative medicine: What are cancer patients seeking?., 2020, 15, e0242048.		O
200	Crowdfunding for complementary and alternative medicine: What are cancer patients seeking?., 2020, 15, e0242048.		0